Clinical Utility of IFIT Proteins in Human Malignancies
Interferon (IFN)-induced proteins with tetratricopeptide repeats (IFITs) are key interferon-stimulated genes (ISGs), and in humans include IFIT1, IFIT2, IFIT3 and IFIT5. These proteins are primarily known for their role in the innate immune response to pathogens. However, growing evidence suggests t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/6/1435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839654685210836992 |
|---|---|
| author | Armen Parsyan Arpitha Kochiyanil Anne C. Bonvissuto Vasudeva Bhat Alison L. Allan |
| author_facet | Armen Parsyan Arpitha Kochiyanil Anne C. Bonvissuto Vasudeva Bhat Alison L. Allan |
| author_sort | Armen Parsyan |
| collection | DOAJ |
| description | Interferon (IFN)-induced proteins with tetratricopeptide repeats (IFITs) are key interferon-stimulated genes (ISGs), and in humans include IFIT1, IFIT2, IFIT3 and IFIT5. These proteins are primarily known for their role in the innate immune response to pathogens. However, growing evidence suggests that IFITs participate in a range of other cellular processes, including cancer development and progression. Notably, IFITs may behave in either a pro-oncogenic or tumor suppressive fashion depending on cancer types and emphasizing their potential dual function in tumorigenesis. Importantly, IFITs have shown potential to be utilized as clinical biomarkers in oncology. Their aberrant expression has been correlated with survival and other clinical outcomes, including resistance to radiotherapy, chemotherapy, targeted treatments and immunotherapy in various cancers. Additionally, they have also been reported to be a part of various clinical predictive models in cancers. This review provides an overview of the current understanding of IFIT proteins’ involvement in cancers, with an emphasis on their emerging roles as clinically relevant biomarkers. |
| format | Article |
| id | doaj-art-cf4b3c0c3d504e8280d5c0c90b92f3b2 |
| institution | Matheson Library |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-cf4b3c0c3d504e8280d5c0c90b92f3b22025-06-25T13:31:56ZengMDPI AGBiomedicines2227-90592025-06-01136143510.3390/biomedicines13061435Clinical Utility of IFIT Proteins in Human MalignanciesArmen Parsyan0Arpitha Kochiyanil1Anne C. Bonvissuto2Vasudeva Bhat3Alison L. Allan4Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, CanadaFaculty of Science, Schulich School of Medicine and Dentistry, Western University, London, ON N6G 5C1, CanadaDepartment of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, CanadaDepartment of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, CanadaDepartment of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, CanadaInterferon (IFN)-induced proteins with tetratricopeptide repeats (IFITs) are key interferon-stimulated genes (ISGs), and in humans include IFIT1, IFIT2, IFIT3 and IFIT5. These proteins are primarily known for their role in the innate immune response to pathogens. However, growing evidence suggests that IFITs participate in a range of other cellular processes, including cancer development and progression. Notably, IFITs may behave in either a pro-oncogenic or tumor suppressive fashion depending on cancer types and emphasizing their potential dual function in tumorigenesis. Importantly, IFITs have shown potential to be utilized as clinical biomarkers in oncology. Their aberrant expression has been correlated with survival and other clinical outcomes, including resistance to radiotherapy, chemotherapy, targeted treatments and immunotherapy in various cancers. Additionally, they have also been reported to be a part of various clinical predictive models in cancers. This review provides an overview of the current understanding of IFIT proteins’ involvement in cancers, with an emphasis on their emerging roles as clinically relevant biomarkers.https://www.mdpi.com/2227-9059/13/6/1435interferon-induced protein with tetratricopeptide repeatsIFIT1IFIT2IFIT3IFIT5cancer |
| spellingShingle | Armen Parsyan Arpitha Kochiyanil Anne C. Bonvissuto Vasudeva Bhat Alison L. Allan Clinical Utility of IFIT Proteins in Human Malignancies Biomedicines interferon-induced protein with tetratricopeptide repeats IFIT1 IFIT2 IFIT3 IFIT5 cancer |
| title | Clinical Utility of IFIT Proteins in Human Malignancies |
| title_full | Clinical Utility of IFIT Proteins in Human Malignancies |
| title_fullStr | Clinical Utility of IFIT Proteins in Human Malignancies |
| title_full_unstemmed | Clinical Utility of IFIT Proteins in Human Malignancies |
| title_short | Clinical Utility of IFIT Proteins in Human Malignancies |
| title_sort | clinical utility of ifit proteins in human malignancies |
| topic | interferon-induced protein with tetratricopeptide repeats IFIT1 IFIT2 IFIT3 IFIT5 cancer |
| url | https://www.mdpi.com/2227-9059/13/6/1435 |
| work_keys_str_mv | AT armenparsyan clinicalutilityofifitproteinsinhumanmalignancies AT arpithakochiyanil clinicalutilityofifitproteinsinhumanmalignancies AT annecbonvissuto clinicalutilityofifitproteinsinhumanmalignancies AT vasudevabhat clinicalutilityofifitproteinsinhumanmalignancies AT alisonlallan clinicalutilityofifitproteinsinhumanmalignancies |